C-Path’s T1D Consortium and Quantitative Medicine Program assisted the team University of Florida with the creation of a clinical trial simulation tool and corresponding article titled "Type 1 Diabetes Prevention Clinical Trial Simulator: Case Reports of Model-informed Drug Development Tool." The article was recently published in CPT: Pharmacometrics & Systems Pharmacology and focuses on the development of a disease progression model-based CTS tool using individual-level data collected from multiple sources. The goal of this tool is to help design more efficient clinical trials that will prevent or delay the onset of T1D. Within the article, the tool is described in depth along with instructions on how to use the tool and case studies. ⏩ Access the article here: https://lnkd.in/gd8mefC3 ⏩ The web-based tool is publicly available here: https://lnkd.in/g_aFYKWk ⏩ Information on C-Path's T1DC here: https://lnkd.in/g9s6mzJ7 Juan Francisco Morales Jagdeep Podichetty, PhD Jackson Burton Klaus Romero Inish O'Doherty, Ph.D. Sarah Kim Sarah David ASCPT Journal Family #CPath #T1D #ASCPTJournalFamily #PSPJournal #drugdevelopment #datasharing #collaboration #globalhealth #diabetes
Critical Path Institute (C-Path)’s Post
More Relevant Posts
-
🌟💊Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509 We are proud to announce that our very own clinical research investigator, Friedeborg Seitz, was a key contributor to a recent study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509 in healthy volunteers. The study, conducted through rigorous Single Rising Dose (SRD) and Multiple Rising Dose (MRD) trials, provided valuable insights into the effects and potential of BI 685509. Highlights include: SRD Trial: 24 participants received single doses of BI 685509 or placebo, with key findings showing rapid absorption and dose-proportional exposure. MRD Trial: 60 participants received varying doses over 14–17 days, with observations of decreased orthostatic dysregulation over time and near-dose-proportional increases in exposure. The study confirmed BI 685509 was generally well tolerated, with manageable side effects. Join us in celebrating this achievement and the ongoing dedication of our team to excellence in clinical research! 👨🔬🔬 Read the full study here: https://lnkd.in/eC-6PwEd #CRS #Innovation #ClinicalResearch #PursuitofExcellence #Mannheim
To view or add a comment, sign in
-
Interesting call for papers from #CPT on a very special and interesting topic. Check it out! #CPTjournal #CallForPapers #EvidenceIntegration #PatientAccess #DrugDevelopment
Mission-driven Chief Medical Officer and Digital Health Strategist | I accelerate value in Oncology, Data Science & Virtual Health through patient-centric, physician-led technology and direct multidisciplinary care
✨ I am thrilled to lead CPT's 2025 special issue: Bench to Budget: Streamlining Evidence Integration to Enhance Drug-Development and Patient Access.💡Now is your opportunity to contribute to this important discussion! The goal of the Clinical Pharmacology & Therapeutics' high-profile “Bench to Budget” special issue is to explore the opportunities and challenges at the intersection of drug development, population health and economic evaluation. We are delighted that Sebastian Schneeweiss joins as Guest Editor. We look forward to receiving your high quality manuscripts by September 30th, 2024. 🗓 Please reach out to me with any questions. For more information, please see the Call for Papers. 📣 https://bit.ly/3KSxXzj Many thanks to the entire special issue Editorial Team Piet Van Der Graaf spiros vamvakas Mai Mehanna, MS, PhD Ya-Feng Wen Alaina Webster and the ASCPT Journal Family
CPT Call for Papers: Bench to Budget: Streamlining the Full Spectrum of Evidence Integration to Enhance Efficiency and Impact of Drug-Development and Patient Access
ascpt.org
To view or add a comment, sign in
-
Pharmacology: Illuminating the Path to Enhanced Healthcare Outcomes 🔬 In the ever-evolving landscape of healthcare, pharmacology stands as a cornerstone in shaping treatment modalities and patient well-being. Embracing the nuances of pharmacotherapy is not only essential but transformative for healthcare professionals striving to optimize care delivery and refine patient outcomes. 💡 This Week's Educational Expedition: - Exploring Novel Drug Therapies: Delve into the intricacies of cutting-edge medications, deciphering their mechanisms of action and potential implications for therapeutic regimens. - Personalized Precision in Medicine: Unravel the intricate tapestry of pharmacogenomics and its profound impact on tailoring treatment plans to individual genetic profiles, ushering in a new era of personalized medicine. - Crafting the Adherence Puzzle: Navigate the labyrinth of medication adherence strategies, uncovering innovative approaches that bolster patient compliance and fortify the foundation of successful treatment outcomes. 📚 Seek Deeper Insight Through Scholarly Discourse: - Aromataris, E., & Pearson, A. (2020). The effectiveness of pharmacotherapy for chronic conditions. *Journal of Clinical Pharmacy and Therapeutics, 45*(1), 12-23. [Read more](https://lnkd.in/ef35sJ6d) - Chen, M., & Wang, X. (2023). Pharmacogenomics and its impact on personalized medicine. *American Journal of Health-System Pharmacy, 80*(7), 563-570. [Explore further](https://lnkd.in/epmckZHe) - Smith, R. D., & Jones, A. (2022). Strategies for improving medication adherence in chronic disease management. *Health Policy Review, 28*(4), 315-329. [Dive into details](https://lnkd.in/esEk-6-E) 🔗 #HealthcareProfessionals #Pharmacotherapy #MedicalEducation #PatientCare #ContinuousLearning Your insights and queries are welcomed in the comments section below! Let's ignite a dialogue that propels us towards a brighter, more informed healthcare future.
To view or add a comment, sign in
-
Eli Lilly’s Mounjaro is able to elicit greater weight loss in overweight or obese patients than Novo Nordisk’s Ozempic, according to the results of a new observational study. The findings, published Monday in JAMA Internal Medicine, showed that patients on Mounjaro lost 2.4% more body weight at three months, compared with those taking Ozempic. Lilly’s GLP-1 treatment widened its lead through six and 12 months of treatment, leading to 4.3% and 6.9% greater weight loss than Ozempic, respectively. The researchers cautioned that their findings have limitations, chief of which is the observational design of the study. Rather than pitting Mounjaro and Ozempic against each other in a controlled, head-to-head clinical trial, Monday’s study drew from electronic health records of patients who had received either drug. This approach could have introduced unmeasured bias and uncertainties into the analysis, according to the researchers. #biotech #biopharma #pharma #Ozempic #Mounjaro #Obesity #WeightLoss
Lilly’s Mounjaro Helps Patients Lose More Weight Than Novo’s Ozempic: Study | BioSpace
biospace.com
To view or add a comment, sign in
-
🔔 13th Biomedicines Webinar 🔔 📚 Pharmacokinetics and Pharmacogenetics in Treating Infections 📅 May 10, 2024 🕣 15:00 (CEST) | 09:00 PM (Beijing) 👩🔬 Event Chair: Prof. Jessica Cusato 👨🔬 👩🔬 Keynote Speakers: Dr. Dario Cattaneo and Prof. Jessica Cusato Webinar registration ➡️ https://lnkd.in/dMKdgRvp In this webinar, we will deal mainly with the main clinical, pharmacologic, and pharmacogenetic sources of variability in the exposure and clinical response to anti-infective agents, with a specific focus on the role of therapeutic drug monitoring and pharmacogenetic testing as reliable diagnostic tools in the daily management of in- and out-patient settings. Finally, the potential role of a fast-track pharmacology at the bedside will be also proposed. 👉 Learn more about the webinar: https://lnkd.in/dHbiMVKr
To view or add a comment, sign in
-
Level Up Unlocked: Diabetes Pharmacology Decoded! Wrapped up an intensive week-long online crash course, "Diabetes Pharmacology Decoded: Bridging Mechanisms to Management," and I'm feeling incredibly grateful for the knowledge boost! This course dove deep into the mechanisms of action for various diabetes medications, providing a clear link between their pharmacological effects and real-world patient management. It was a fantastic opportunity to: * Gain in-depth knowledge of different drug classes used in diabetes treatment. * Explore the latest advancements in diabetes medications. * Refine my ability to apply pharmacological principles for optimal patient care. **Huge thanks to the Med Sparkles for this insightful and engaging program!** This certificate is a badge of honor and a testament to my commitment to continuous learning in the ever-evolving field of diabetes care. #ContinuingEducation #OnlineLearning #PatientCare #DiabetesPharmacologyDecoded #Medsparkles
To view or add a comment, sign in
-
📢 Register for the upcoming DiMe webinar on October 30, 11am EDT: Regulatory Pathways for Qualification and Acceptance of Digital Health Technology-Derived Clinical Trial Endpoints: Considerations for Sponsors and join Jessie Bakker, MS PhD and Elena Izmailova as they discuss the available regulatory approaches to support the increasing deployment of DHTs within the clinical research setting and to help advance regulatory science in the field of digital medicine, based on the recent publication in American Society for Clinical Pharmacology & Therapeutics' Journal. Read the article here: https://lnkd.in/eDGy_QBs REGISTER HERE for the webinar👇 https://lnkd.in/eZEPAebt #DiMe #journalclub #DHT #drugdevelopment #Regulatory
To view or add a comment, sign in
-
Study of causal impact of statins on susceptibility to osteoarthritis: insights from a two-sample Mendelian randomization analysis. Statins reduce the risk of osteoarthritis, aligning with the results of observational studies. Further research is essential to validate these results and explore the underlying mechanisms in detail. Derek Stewart European Society of Clinical Pharmacy (ESCP) Yolande Hanssens Vibhu Paudyal Shusen Sun Filipa Alves da Costa Matej Štuhec PharmD PhD Univ.-Prof. Dr. Anita Weidmann #pharmacy #pharmacists #pharmacylife #clinicalpharmacy #pharmaceuticalcare #pharmacycollege #pharmacystudents #pharmacytechnicians https://lnkd.in/drpr-FFP
Causal impact of statins on susceptibility to osteoarthritis: insights from a two-sample Mendelian randomization analysis - International Journal of Clinical Pharmacy
link.springer.com
To view or add a comment, sign in
-
🔬 Current Diabetes Reviews – Volume 20, Issue 10, 2024 🔬 📈 Impact Factor: 2.4 🗂️ Indexed In: Scopus, ESCI, MEDLINE/PubMed Stay at the forefront of diabetes research with our latest issue. Explore comprehensive reviews and original research on diabetes pathogenesis, complications, pharmacology, clinical care, and more. Read our latest articles and submit your research to contribute to advancements in diabetes care! https://bit.ly/4dFNAqf #DiabetesResearch #ClinicalCare #Innovation #Research
To view or add a comment, sign in
-
📣𝗢𝗻𝗹𝘆 𝗼𝗻𝗲 𝘄𝗲𝗲𝗸 𝗹𝗲𝗳𝘁 until our upcoming webinar: 𝗚𝗲𝘁𝘁𝗶𝗻𝗴 𝗚𝗥𝗜𝗣 𝗼𝗻 𝗠𝗔𝗦𝗛 𝗮𝗳𝘁𝗲𝗿 𝗟𝗜𝗧𝗠𝗨𝗦! Secure your spot now and gain insights into: - The Impact of Disease Prevalence on the Efficacy of Noninvasive Diagnostic Methods - Leveraging Lifestyle Interventions for Enhanced Patient Stratification - Optimizing MASH Management through Clinical Pathways from Primary Care and Endocrinology Clinics https://lnkd.in/g5a9kyjV
Register for our upcoming MASH webinar | Julius Clinical
app.livestorm.co
To view or add a comment, sign in
8,698 followers